Objective  To systematically evaluate the pharmacoeconomic research on herpes zoster (HZ) vaccine administration, providing reference for related research and prevention of HZ.

  Methods  Based on the theme words such as 'herpes zoster', 'herpes zoster vaccines', 'pharmacoeconomics', 'cost-effectiveness analysis', the literature of pharmacoeconomic study on herpes zoster vaccination was retrieved from 4 Chinese databases and 4 English databases from our library to January 2023. Two researchers independently screened the retrieved literature twice. Relevant information of the included literature was extracted according to the Guidelines for Conducting Economic Evaluation of Immunization Programs of the World Health Organization. The quality of pharmacoeconomic studies on herpes zoster vaccination in the included literature was evaluated using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS2022). Descriptive analysis and qualitative systematic evaluation were conducted on research perspectives, model structures, parameter selection, evaluation results, and sensitivity analyses.

  Results  A total of 43 English literature on the economic study of herpes zoster vaccine vaccination drugs were included, published from April 2001 to June 2022, among which 3 articles focused on the Chinese population. The research quality scores of 23 articles were > 80% (high quality), and 20 articles scored between 65% and 80% (mid-high quality). Among the 39 articles, the economic study of herpes zoster vaccine vaccination drugs was evaluated using cost-utility analysis (CUA); 31 articles evaluated the economic study of herpes zoster vaccine vaccination drugs from a societal perspective. The results of 42 articles showed that immunocompetent individuals who received herpes zoster vaccine had economic benefits, and the age of vaccination, threshold, vaccine cost, and vaccination scheme had significant effects on the results. Among the 3 articles focusing on the Chinese population, 2 articles showed that vaccination with herpes zoster vaccine was economically beneficial, and 1 article showed that the elderly aged 60 to 70 years had the most economic benefits from herpes zoster vaccine vaccination.

  Conclusion  The economic study of vaccination with high-quality herpes zoster vaccine based on domestic data in China is recommended to provide evidence for immunization and prevention of HZ.